Skip to main content
. 2012 Feb 22;103(4):791–796. doi: 10.1111/j.1349-7006.2012.02225.x

Table 1.

Clinicopathologic features according to epidermal growth factor receptor R521K polymorphism status in KRAS wild‐type colorectal carcinoma patients (= 112)

Characteristics G/G (wild‐type) (%) G/A or A/A (%) P
All patients 36 (100) 76 (100)
Age, years
<50 14 (38.9) 26 (34.2) 0.63
≥50 22 (61.1) 50 (65.8)
Gender
Male 25 (69.4) 55 (72.4) 0.75
Female 11 (30.6) 21 (27.6)
Performance status
0 26 (72.2) 53 (69.7) 0.79
1, 2 10 (27.8) 23 (30.3)
Primary tumor
Colon 24 (62.1) 57 (69.0) 0.36
Rectum 12 (37.9) 19 (31.0)
VEGF expression
Higher (≥10% positive cells) 24 (66.7) 22 (28.9) <0.01
Lower (<10% positive cells) 12 (33.3) 54 (71.1)
At least one tumor ≥6 cm
Present 20 (55.6) 24 (31.6) 0.02
Absent 16 (44.4) 52 (68.4)
Histologic differentiation
Good/moderate 23 (63.9) 65 (85.5) 0.01
Poor 13 (36.1) 11 (14.5)
Lymphovascular invasion
Present 25 (69.4) 30 (39.5) <0.01
Absent 11 (30.6) 46 (60.5)
ERCC1 codon 118 genotype
C/C (wild‐type) 17 (47.2) 35 (46.1) 0.91
C/T or T/T 19 (52.8) 41 (53.9)
XPD codon 751 status
Lys/Lys (wild‐type) 31 (86.1) 63 (82.9) 0.67
Lys/Gln 5 (13.9) 13 (17.1)
TSER 28‐bp polymorphism
2R/2R or 2R/3R 12 (33.3) 27 (35.5) 0.82
3R/3R 24 (66.7) 49 (64.5)

bp, base pair; ERCC1, excision repair cross‐complementing group 1; TSER, 5′‐enhancer region of the thymidylate synthase gene; VEGF, vascular endothelial growth factor; XPD, xeroderma pigmentosum group D.